Information Provided By:
Fly News Breaks for October 15, 2018
BSX
Oct 15, 2018 | 07:51 EDT
RBC Capital analyst Glenn Novarro raised his price target on Boston Scientific to $42 and kept his Top Pick rating, saying the first-half momentum in the Medical Surgery, Rhythm & Neuro, and Cardiovascular segments should persist in Q3. The analyst expects the company's operational growth to be around 8% in the quarter and potentially as high as 10% in 2019-2020.